Hysterosalpingo-Foam Ultrasonography Combined With Power Doppler, Compared With Laparoscopy in Tubal Patency Assessment in Cases of Infertility

NCT ID: NCT05209542

Last Updated: 2022-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

119 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-09

Study Completion Date

2021-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Women presenting with primary or secondary infertility and are undergoing investigation of tubal patency assessment will be subjected to:

* The examination is performed between days 5 and 10 of the menstrual cycle.
* Routine antibiotic prophylaxis using oral Azithromycin the day before and routine administration of NSAID rectal suppository one hour before the procedure
* Initially, real-time 2D +/- 3D vaginal ultrasound assessment of the pelvis
* The cervix is to be visualized with a Cusco speculum and to be cleaned with an antiseptic then A No. 5 pediatric Foley catheter will be introduced into the cervical os, using a tenaculum if necessary. The balloon is to be positioned in the lower uterine cavity and to be inflated with 2 ml of saline to prevent backflow of contrast medium through the cervix then the speculum will be removed and the vaginal transducer is going to be reintroduced in the longitudinal plane to confirm correct placement of the catheter.
* Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging
* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection.
* Tubal patency and quality of visualization are classified according the following parameters:

1. Flow over the whole length of the tube, fimbrial outflow or peritoneal spillage of contrast provided definite evidence of complete (i.e. proximal and distal) tubal patency.
2. Paracornual flow only without visualization of fimbrial outflow or peritoneal spillage suggests at least proximal patency.
3. Contrast filling of the endometrial cavity without cornual flow suggests possible tubal occlusion.
4. Technical difficulty making tubal evaluation impossible
* Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Women in the reproductive age group between 20 and 40 years old presenting with primary or secondary infertility ( either unexplained or suspected tubal factor by history taking ) and are undergoing investigation of tubal patency assessment

Each patient in this study will be subjected to:

* The examination is performed between days 5 and 10 of the menstrual cycle, the patient in gynecological position, preferably with the aid of one assistant.
* Routine antibiotic prophylaxis using oral Azithromycin the day before and routine administration of NSAID rectal suppository one hour before the procedure
* Initially, real-time 2D +/- 3D vaginal ultrasound assessment of the pelvic organs is to be performed using Samsung Elite with endovaginal probe of frequency 6-12 MHz
* The cervix is to be visualized with a Cussco speculum and to be cleaned with an antiseptic then A No. 5 pediatric Foley catheter will be introduced into the cervical os, using a tenaculum if necessary. The balloon is to be positioned in the lower uterine cavity and to be inflated with 2 ml of saline to prevent backflow of contrast medium through the cervix then the speculum will be removed and the vaginal transducer is going to be reintroduced in the longitudinal plane to confirm correct placement of the catheter.
* The foam contrast agent is created by combining 3-4mL of 2% lidocaine gel 12-13mL of saline and 3mL air.
* The assistant creates the foam immediately before application, moving the mixture between two connected 20-mL syringes, until a whitish suspension is obtained (approximately 10-20 times).
* Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging
* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection.
* Acquisition without Doppler usually takes less than 5 s, while acquisition with power Doppler is longer(approximately 10 s)
* After dataset acquisition, Images will be stored as 2D still images, 2D clips +/- 3D volumes. the patient is to be discharged and final diagnosis is made based on the real-time observations and, if available, offline analyses of acquired datasets.
* Tubal patency and quality of visualization are classified according the following parameters:

1. Flow over the whole length of the tube, fimbrial outflow or peritoneal spillage of contrast provided definite evidence of complete (i.e. proximal and distal) tubal patency.
2. Paracornual flow only without visualization of fimbrial outflow or peritoneal spillage suggests at least proximal patency.
3. Contrast filling of the endometrial cavity without cornual flow suggests possible tubal occlusion.
4. Technical difficulty making tubal evaluation impossible e.g. absent filling of the endometrial cavity due to backflow of contrast, inability to introduce the catheter into the cervical os or maintain the catheter in the correct position preventing instillation of contrast into the endometrial cavity.
* Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia.
* The raters are to be blinded to the results of the ultrasound examination until endoscopic diagnosis is to be performed
* Comparison between the results of the above mentioned techniques will be done and statistical analysis of the results will be carried out

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility of Tubal Origin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hysterosalpingo-Foam Ultrasonography

3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging

Group Type ACTIVE_COMPARATOR

Hysterosalpingo-Foam Ultrasonography

Intervention Type PROCEDURE

* Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging
* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection

Laparoscopy

Intervention Type PROCEDURE

• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia

laparoscopy

• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia

Group Type ACTIVE_COMPARATOR

Hysterosalpingo-Foam Ultrasonography

Intervention Type PROCEDURE

* Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging
* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection

Laparoscopy

Intervention Type PROCEDURE

• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hysterosalpingo-Foam Ultrasonography

* Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging
* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection

Intervention Type PROCEDURE

Laparoscopy

• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Sexually active women in the reproductive age group between 20 and 40 years

* History of primary or secondary infertility ( either unexplained or suspected tubal factor by history taking )
* Tubal factor has not been investigated before or has been investigated with inconclusive results

Exclusion Criteria

* Age less than 20 or above 40 years.
* Using contraception.
* Undiagnosed pregnancy.
* known allergy to lidocaine.
* active pelvic inflammatory disease or genital tract bleeding.
* Patent both tubes as assessed previously ( no need for exposure to further Investigation.
Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed M Maged, MD

professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed Mohamed Maged M ElGoly

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kasr Alainy medical school

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

63

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.